Sanofi bol­sters its po­si­tion on mul­ti­ple scle­ro­sis with a $765M BTK li­cens­ing deal

Sanofi is snap­ping up an ear­ly-stage pro­gram from San Fran­cis­co’s Prin­cip­ia Bio­phar­ma, shoring up the phar­ma gi­ant’s po­si­tion in mul­ti­ple scle­ro­sis.

Sanofi will write a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER